JP2015535247A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535247A5
JP2015535247A5 JP2015539666A JP2015539666A JP2015535247A5 JP 2015535247 A5 JP2015535247 A5 JP 2015535247A5 JP 2015539666 A JP2015539666 A JP 2015539666A JP 2015539666 A JP2015539666 A JP 2015539666A JP 2015535247 A5 JP2015535247 A5 JP 2015535247A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
salt
pharmaceutical composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015539666A
Other languages
English (en)
Japanese (ja)
Other versions
JP6243921B2 (ja
JP2015535247A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/065418 external-priority patent/WO2014066132A1/en
Publication of JP2015535247A publication Critical patent/JP2015535247A/ja
Publication of JP2015535247A5 publication Critical patent/JP2015535247A5/ja
Application granted granted Critical
Publication of JP6243921B2 publication Critical patent/JP6243921B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015539666A 2012-10-26 2013-10-17 Bace阻害剤 Expired - Fee Related JP6243921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718728P 2012-10-26 2012-10-26
US61/718,728 2012-10-26
PCT/US2013/065418 WO2014066132A1 (en) 2012-10-26 2013-10-17 Bace inhibitors

Publications (3)

Publication Number Publication Date
JP2015535247A JP2015535247A (ja) 2015-12-10
JP2015535247A5 true JP2015535247A5 (enExample) 2016-12-01
JP6243921B2 JP6243921B2 (ja) 2017-12-06

Family

ID=49515508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015539666A Expired - Fee Related JP6243921B2 (ja) 2012-10-26 2013-10-17 Bace阻害剤

Country Status (17)

Country Link
US (1) US9328124B2 (enExample)
EP (1) EP2912041B1 (enExample)
JP (1) JP6243921B2 (enExample)
CN (1) CN104755484B (enExample)
CA (1) CA2886507C (enExample)
CY (1) CY1118623T1 (enExample)
DK (1) DK2912041T3 (enExample)
ES (1) ES2616835T3 (enExample)
HR (1) HRP20170025T1 (enExample)
HU (1) HUE031764T2 (enExample)
LT (1) LT2912041T (enExample)
ME (1) ME02576B (enExample)
PL (1) PL2912041T3 (enExample)
PT (1) PT2912041T (enExample)
RS (1) RS55561B1 (enExample)
SI (1) SI2912041T1 (enExample)
WO (1) WO2014066132A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134341A1 (en) 2013-03-01 2014-09-04 Amgen Inc. Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
AP2015008716A0 (en) 2013-03-08 2015-09-30 Amgen Inc Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
TWI684452B (zh) * 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
JP6576433B2 (ja) 2014-08-08 2019-09-18 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としてのシクロプロピル縮合チアジン−2−アミン化合物及び使用方法
WO2017024180A1 (en) 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors
CA3047287A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
JP7148518B2 (ja) 2016-12-15 2022-10-05 アムジエン・インコーポレーテツド β-セクレターゼ阻害剤としての二環式チアジンおよびオキサジン誘導体ならびに使用方法
MX387729B (es) 2016-12-15 2025-03-18 Amgen Inc Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso.
WO2018112083A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
CN106632001A (zh) * 2016-12-28 2017-05-10 山东诚汇双达药业有限公司 一种4‑(溴乙酰基)吡啶氢溴酸盐的制备方法
CN110452179A (zh) * 2019-06-25 2019-11-15 南京普锐达医药科技有限公司 一种2-氯-4-甲氧基-5-氰基嘧啶的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
ES2548774T3 (es) 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
US8541427B2 (en) 2008-04-22 2013-09-24 Merck, Sharp & Dohme, Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
AU2009258496B8 (en) 2008-06-13 2014-06-26 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
JPWO2011071109A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Similar Documents

Publication Publication Date Title
JP2015535247A5 (enExample)
ES2613931T3 (es) Compuestos peptídicos para tratar el estado epiléptico refractario
JP2016528301A5 (enExample)
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2014517050A5 (enExample)
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2013501731A5 (enExample)
JP2020536905A5 (enExample)
JP2016534063A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
TW200600492A (en) Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
JP2010500376A5 (enExample)
EA200702445A1 (ru) Соединения тиазола и способы их применения
JP2016525121A5 (enExample)
RU2013155586A (ru) [1,3]оксазины
JP2007507494A5 (enExample)
JP2020507589A5 (enExample)
JP2016522254A5 (enExample)
JP2006503850A5 (enExample)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2015522018A5 (enExample)
JP2016516773A5 (enExample)
JP2015517523A5 (enExample)
TN2020000160A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE